PubMed, doi:10.1016/j.envint.2019.02.006.Chaudhary, Amit, and Kristine L
The prescription must be specifically for weight loss not for treating other conditions
Definitely controls appetite
GIP and GLP-1 receptor activity: These hormones naturally signal the body to release insulin, slow gastric emptying, and decrease hunger cues
Location: Indianapolis, IndianaWarning Letter Date: September 9, 2025FDA Department Issuing Warning: Center for Drug Evaluation and Research (CDER)Type of Warning: False & Misleading Claims/Misbranded DrugsSubject of Violation: An Oprah Special: Shame, Blame, and the Weight Loss Revolution, regarding Zepbound (tirzepatide) and Mounjaro (tirzepatide)FDA Warning: In the program, which aired on television in 2024 and until recently was available continuously on the ABC website and through various streaming services, Eli Lilly promoted Mounjaro and Zepbound in a manner that failed to present the serious risks of these drug products in a truthful and nonmisleading manner, despite FDAs prior correspondence (advisory comments dated June 13, 2022 and June 21, 2022)